Archives

FATP2 at the crossroads of fatty acid transport, lipotoxicity, and complex disease

Type 2 diabetes mellitus affects over 38 million Americans, with diabetic kidney disease as a major complication partly driven by lipotoxicity. Fatty acid transport protein 2 (FATP2) regulates uptake and activation of long-chain fatty acids, making it a therapeutic target in metabolic disease. In this issue of the JCI, Khan et al. investigated FATP2 in […]

Coprescribing GLP-1 Receptor Agonists and Lifestyle

To the Editor The importance of integrating lifestyle modification when initiating glucagon-like peptide-1 and dual receptor agonists (GLP-1 RAs) for type 2 diabetes and/or obesity cannot be overstated. As referral to a registered dietitian or lifestyle medicine specialist is ideal but not always feasible, providing clinicians with practical, evidence-based resources for use when coprescribing GLP-1 […]

Home hospital care demonstrates success in rural communities

One in five people in the United States live in a rural area. Patients in rural communities often struggle to access care because of travel difficulties, high costs and limited resources, leading to worse medical outcomes. With over 150 rural hospital closures since 2010, innovative approaches to care delivery in rural areas are needed.

Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program

Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug purchased through LillyDirect. Both pharmas recently struck a deal with the White House for cheaper prices via the yet-to-be-launched TrumpRx.